Abstract 2752
Background
The tumor immune microenvironment (TIME) may hold critical information for developing and optimizing immuno-therapeutic approaches, identifying predictive signatures, and selecting the most adequate treatment option for a given patient. Tissue phenomics facilitates the use of the TIME to derive predictive conclusions. The visual information content in histological sections is systematically converted into numerical readouts using artificial intelligence (AI). Resulting quantitative descriptors, phenes, of detected structures are mined to yield local expression profiles; this spatial data aggregation detects categories of local environments, which are correlated to clinical, genomic or other -omics data to identify relevant cohort subpopulations.
Methods
Exploration of this technology is illustrated by various examples on different cohorts of NSCLC patients: A categorization of n = 45 non-IO-treated patients with respect to local immune profiles learned via AI in a hypothesis-free scenario was examined. A deep learning based PD-L1 scoring was compared to 3 pathologist’s scoring on n = 40 durvalumab-treated patients using the cutoff 25% of tumor cells staining positive for PD-L1 at any intensity. The predictive value of a digital signature combining cell densities of PD-L1 and CD8+ was tested on n = 163 durvalumab-treated and n = 199 non-IO-treated samples.
Results
A categorization into biologically interpretable classes learned by AI illustrates the exploratory benefits of tissue phenomics. The scoring algorithm could reproduce survival prediction when compared to pathologist’s visual scoring.The digital signature suggests a predictive value for patient stratification into responders and non-responders for durvalumab, while no prognostic value could be found on the non-IO-treated patients. Kaplan-Meier plots for the 2 latter examples will be presented in the poster.
Conclusions
Tissue phenomics facilitates the quantitative assessment of the tumor geography and may lead to improved tools for biomarker analysis and diagnosis. Analysis on larger and prospective datasets are to be conducted in the future to strengthen the findings.
Clinical trial identification
All of these results have been generated retrospectively from samples unrelated to a trial or related to the durvalumab-trial NCT01693562.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim, MedImmune, Definiens AG.
Disclosure
M. Groher: Full / Part-time employment: Definiens AG. J. Zimmermann: Shareholder / Stockholder / Stock options: AstraZeneca; Full / Part-time employment: Definiens AG. H. Musa: Full / Part-time employment: Boehringer Ingelheim. A. Ackermann: Full / Part-time employment: Boehringer Ingelheim. M. Surace: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. J. Rodriguez-Canales: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. Rebelatto: Shareholder / Stackeholder / Stock options: AstraZenec LLC; Full / Part-time employment: AstraZeneca LLC. K. Steele: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca; Spouse / Financial dependant: Arcellx LLC. A. Kapil: Full / Part-time employment: Definiens AG. N. Brieu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Definiens AG. L. Rognoni: Full / Part-time employment: Definiens AG. F. Segerer: Full / Part-time employment: Definiens AG. A. Spitzmüller: Full / Part-time employment: Definiens AG. T. Tan: Full / Part-time employment: Definiens AG. A. Schäpe: Full / Part-time employment: Definiens AG. G. Schmidt: Full / Part-time employment: Definiens AG; Shareholder / Stockholder / Stock options: AstraZeneca.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract